All Products

Featured Products

Newest Products

Research Areas

PIK-90
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406326

CAS#: 677338-12-4

Description: PIK-90 is a potent PI3K inhibitor with potential anticancer activity.


Price and Availability

Size Price Shipping out time Quantity
10mg USD 110 2 Weeks
25mg USD 150 2 Weeks
50mg USD 250 2 Weeks
100mg USD 450 2 Weeks
200mg USD 850 2 Weeks
500mg USD 1650 2 Weeks
1g USD 2650 2 Weeks
2g USD 3950 2 Weeks
Inquire bulk and customized quantity
Pricing updated 2021-01-27. Prices are subject to change without notice.

PIK-90, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406326
Name: PIK-90
CAS#: 677338-12-4
Chemical Formula: C18H17N5O3
Exact Mass: 351.13314
Molecular Weight: 351.36
Elemental Analysis: C, 61.53; H, 4.88; N, 19.93; O, 13.66


Synonym: PIK90; PIK90; PIK 90.

IUPAC/Chemical Name: N-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide

InChi Key: ZJAVHOMVDCMAMF-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H17N5O3/c1-25-13-6-5-12-14(15(13)26-2)21-18(23-9-8-20-16(12)23)22-17(24)11-4-3-7-19-10-11/h3-7,10H,8-9H2,1-2H3,(H,21,22,24)

SMILES Code: O=C(NC1=NC2=C(C=CC(OC)=C2OC)C3=NCCN13)C4=CN=CC=C4


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Storage Condition:
0– 4 oC for short term (weeks to 1 month) or -20 oC for long terms (months to years).

Solubility:
Soluble in DMSO, not soluble in water.

Shelf Life:
>2 years if stored properly.

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


Additional Information


References

1: Cheng CK, Gustafson WC, Charron E, Houseman BT, Zunder E, Goga A, Gray NS, Pollok B, Oakes SA, James CD, Shokat KM, Weiss WA, Fan QW. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12722-7. doi: 10.1073/pnas.1202492109. Epub 2012 Jul 16. PubMed PMID: 22802621; PubMed Central PMCID: PMC3411950.

2: Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009 May 28;113(22):5549-57. doi: 10.1182/blood-2008-06-165068. Epub 2009 Mar 24. PubMed PMID: 19318683.

3: Zhang TT, Okkenhaug K, Nashed BF, Puri KD, Knight ZA, Shokat KM, Vanhaesebroeck B, Marshall AJ. Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production. J Allergy Clin Immunol. 2008 Oct;122(4):811-819.e2. doi: 10.1016/j.jaci.2008.08.008. PubMed PMID: 19014771.

4: Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 2007 Sep 1;67(17):7960-5. PubMed PMID: 17804702; PubMed Central PMCID: PMC2597547.